EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
about
Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse.The Evolving Role of Nuclear Medicine and Molecular Imaging: Theranostics and Personalized Therapeutic Applications.EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.
P2860
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
EANM guideline for radionuclid ...... ion-resistant prostate cancer.
@en
EANM guideline for radionuclid ...... ion-resistant prostate cancer.
@nl
type
label
EANM guideline for radionuclid ...... ion-resistant prostate cancer.
@en
EANM guideline for radionuclid ...... ion-resistant prostate cancer.
@nl
prefLabel
EANM guideline for radionuclid ...... ion-resistant prostate cancer.
@en
EANM guideline for radionuclid ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P50
P1476
EANM guideline for radionuclid ...... tion-resistant prostate cancer
@en
P2093
Alexander Becherer
Alexander Heinzel
Andreas Bockisch
Bernd J Krause
Eva Fricke
Lilli Geworski
Lisa Bodei
Michael Andreeff
Michael Gabriel
Thomas Krause
P2860
P2888
P304
P356
10.1007/S00259-017-3900-4
P577
2017-12-12T00:00:00Z